Sci Rep:PD-L1、E-cadherin、CD24和VEGFR2是上皮癌干细胞的标记并且与快速肿瘤发生相关

2017-09-07 AlexYang MedSci原创

癌症细胞同时需要迁移和致瘤特性从而在原始微环境外建立转移性肿瘤。鉴定迁移癌症干细胞的特征和致瘤特性对预测病人预后和对抗转移是非常重要的。最近,有研究人员建立了1个上皮的和2个间质的细胞系,这这些细胞系来源于膀胱癌病人的腹水(细胞已经迁移到原发肿瘤外面)。对这些细胞性的分析表明,在无毛鼠中,具有表面PD-L1、E-cadherin、CD24和VEGFR2表达的上皮细胞可以在原发肿瘤微环境外迅速形成肿

癌症细胞同时需要迁移和致瘤特性从而在原始微环境外建立转移性肿瘤。鉴定迁移癌症干细胞的特征和致瘤特性对预测病人预后和对抗转移是非常重要的。

最近,有研究人员建立了1个上皮的和2个间质的细胞系,这这些细胞系来源于膀胱癌病人的腹水(细胞已经迁移到原发肿瘤外面)。对这些细胞性的分析表明,在无毛鼠中,具有表面PD-L1、E-cadherin、CD24和VEGFR2表达的上皮细胞可以在原发肿瘤微环境外迅速形成肿瘤,显示了免疫逃避、多能性增加、钙信号增加、转化和新E-钙黏素-RalBP1互作等特性。另外,这些间质细胞,从另一方面来说,展示了组成的TGF-β信号,并且致瘤作用较弱。因此,研究人员指出,以具有快速致癌作用特性的上皮癌干细胞为靶标,在未来也许能够帮助对抗转移。

原始出处:

Goodwin G. Jinesh, Ganiraju C. Manyam, Chinedu O. Mmeje et al. Surface PD-L1, E-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis. Sci Rep. 29 August 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=244510, encodeId=49d8244510e6, content=学习了.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Sat Sep 16 07:11:17 CST 2017, time=2017-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254933, encodeId=44831254933c3, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368486, encodeId=5b8c1368486ff, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407288, encodeId=f46b140e28847, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18347, encryptionId=d5b01834e3a, topicName=VEGFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8d2627959, createdName=jml2010, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534334, encodeId=f0cd153433478, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539300, encodeId=b70315393001b, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544982, encodeId=a0181544982aa, content=<a href='/topic/show?id=7a0fe1289c2' target=_blank style='color:#2F92EE;'>#癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71289, encryptionId=7a0fe1289c2, topicName=癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=340013676140, createdName=1249898am19暂无昵称, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=)]
    2017-09-16 lofter

    学习了.感谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=244510, encodeId=49d8244510e6, content=学习了.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Sat Sep 16 07:11:17 CST 2017, time=2017-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254933, encodeId=44831254933c3, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368486, encodeId=5b8c1368486ff, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407288, encodeId=f46b140e28847, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18347, encryptionId=d5b01834e3a, topicName=VEGFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8d2627959, createdName=jml2010, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534334, encodeId=f0cd153433478, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539300, encodeId=b70315393001b, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544982, encodeId=a0181544982aa, content=<a href='/topic/show?id=7a0fe1289c2' target=_blank style='color:#2F92EE;'>#癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71289, encryptionId=7a0fe1289c2, topicName=癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=340013676140, createdName=1249898am19暂无昵称, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=)]
    2017-09-09 smartjoy
  3. [GetPortalCommentsPageByObjectIdResponse(id=244510, encodeId=49d8244510e6, content=学习了.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Sat Sep 16 07:11:17 CST 2017, time=2017-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254933, encodeId=44831254933c3, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368486, encodeId=5b8c1368486ff, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407288, encodeId=f46b140e28847, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18347, encryptionId=d5b01834e3a, topicName=VEGFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8d2627959, createdName=jml2010, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534334, encodeId=f0cd153433478, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539300, encodeId=b70315393001b, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544982, encodeId=a0181544982aa, content=<a href='/topic/show?id=7a0fe1289c2' target=_blank style='color:#2F92EE;'>#癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71289, encryptionId=7a0fe1289c2, topicName=癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=340013676140, createdName=1249898am19暂无昵称, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=244510, encodeId=49d8244510e6, content=学习了.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Sat Sep 16 07:11:17 CST 2017, time=2017-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254933, encodeId=44831254933c3, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368486, encodeId=5b8c1368486ff, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407288, encodeId=f46b140e28847, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18347, encryptionId=d5b01834e3a, topicName=VEGFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8d2627959, createdName=jml2010, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534334, encodeId=f0cd153433478, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539300, encodeId=b70315393001b, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544982, encodeId=a0181544982aa, content=<a href='/topic/show?id=7a0fe1289c2' target=_blank style='color:#2F92EE;'>#癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71289, encryptionId=7a0fe1289c2, topicName=癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=340013676140, createdName=1249898am19暂无昵称, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=)]
    2017-09-09 jml2010
  5. [GetPortalCommentsPageByObjectIdResponse(id=244510, encodeId=49d8244510e6, content=学习了.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Sat Sep 16 07:11:17 CST 2017, time=2017-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254933, encodeId=44831254933c3, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368486, encodeId=5b8c1368486ff, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407288, encodeId=f46b140e28847, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18347, encryptionId=d5b01834e3a, topicName=VEGFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8d2627959, createdName=jml2010, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534334, encodeId=f0cd153433478, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539300, encodeId=b70315393001b, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544982, encodeId=a0181544982aa, content=<a href='/topic/show?id=7a0fe1289c2' target=_blank style='color:#2F92EE;'>#癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71289, encryptionId=7a0fe1289c2, topicName=癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=340013676140, createdName=1249898am19暂无昵称, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=)]
    2017-09-09 liuyiping
  6. [GetPortalCommentsPageByObjectIdResponse(id=244510, encodeId=49d8244510e6, content=学习了.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Sat Sep 16 07:11:17 CST 2017, time=2017-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254933, encodeId=44831254933c3, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368486, encodeId=5b8c1368486ff, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407288, encodeId=f46b140e28847, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18347, encryptionId=d5b01834e3a, topicName=VEGFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8d2627959, createdName=jml2010, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534334, encodeId=f0cd153433478, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539300, encodeId=b70315393001b, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544982, encodeId=a0181544982aa, content=<a href='/topic/show?id=7a0fe1289c2' target=_blank style='color:#2F92EE;'>#癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71289, encryptionId=7a0fe1289c2, topicName=癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=340013676140, createdName=1249898am19暂无昵称, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=244510, encodeId=49d8244510e6, content=学习了.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Sat Sep 16 07:11:17 CST 2017, time=2017-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254933, encodeId=44831254933c3, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368486, encodeId=5b8c1368486ff, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407288, encodeId=f46b140e28847, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18347, encryptionId=d5b01834e3a, topicName=VEGFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8d2627959, createdName=jml2010, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534334, encodeId=f0cd153433478, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539300, encodeId=b70315393001b, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544982, encodeId=a0181544982aa, content=<a href='/topic/show?id=7a0fe1289c2' target=_blank style='color:#2F92EE;'>#癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71289, encryptionId=7a0fe1289c2, topicName=癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=340013676140, createdName=1249898am19暂无昵称, createdTime=Sat Sep 09 12:20:00 CST 2017, time=2017-09-09, status=1, ipAttribution=)]

相关资讯

J Royal Soci Inter:阿司匹林预防癌症让人又爱又恨

研究人员报道称,每日使用阿司匹林可能能够降低结肠癌的风险,也可能使疾病更难治疗。他们提醒称,这项基于数学建模的新发现,如果在统计学和实验室中确认,将意味着使用阿司匹林抵御结肠癌可能会付出高昂的成本。

出国看病能否让国内癌症治疗实现“弯道超车”?

国内临床医疗技术与美国医疗的差距是不争的事实,特别体现在癌症、心脏病等重大疾病上。

Nat Commu:PARP抑制剂成功阻断前列腺癌的复发

可以减少男性患前列腺癌复发的开创性的研究近日发表在《自然》杂志上。抗荷尔蒙疗法是治疗前列腺癌的常见方法,有助于通过降低雄性激素的水平,来阻断肿瘤生长。在这个深入的研究中,一个由英国科学家领导的国际小组调查了抗荷尔蒙治疗对前列腺癌患者样本的影响。

Neuropharmacology:非精神类大麻素能够减慢癌症生长速度

有些癌症喜欢骨头。它们往往能在营养丰富的环境中茁壮成长,同时吞噬着维持它们的生存的底物,并且释放引起疼痛的炎症物质,当疼痛非常严重的时候,患者经常会服用阿片类药物来减轻痛苦。

Con Sci Phy Onc:“微流控”细胞培养系统,为癌症个性化治疗带来新突破

近日,普林斯顿大学的科学家在《聚合科学物理肿瘤学杂志》(Convergent Science Physical Oncology)上发表了他们的研究结果:利用微流控技术开发了一种全新的细胞培养系统,可以直接实时观察癌细胞耐药性的发展,用于临床癌症药物开发和筛选。

Sci Trans Med:新黑科技——10秒钟测出癌症,准确率将近百分之百

一组来自德克萨斯大学奥斯汀分校的科学家们发明了一种强大的工具,可以快速而准确地在手术过程中识别癌组织,交付结果大约10秒中,比现有技术快150倍。名为MasSpec笔的设备是一种创新的手持设备,可以让外科医生在几秒钟之内准确判断出癌变组织,帮助提高治疗效果,并减少癌症复发的可能性。研究结果发表在近期出版的《科学转化医学》杂志上。